Monkey 30 0.483 0.24 0.1 0.07 1 week, oral 150 5.44 6.16 1.5 1.7 gavage (DM08018) 300 982 411 266 111 Mouse, 25 13.5 13.8 3.7 3.7 100 256 417 69 113 Hemizygous (transgenic). 200 983 1,600 266 434 6 (oral gavage), carcinogenicity (DM11012) Rat, 50 (M) 20.7 - 5.6 - 2 year (oral 75 (M) 58.1 - 16 - gavage), carcinogenicity 193 - 52 125 - (DM11023) (M) 40 (F) - 51.5 - 14 60 (F) - 162 - 44 80 (F) - 202 - 55 CByB6F1 Hybrid 50 16.4 18.6 4.4 5.0 Mice 2 oral Toxicokinetic, 150 90.6 94.9 24.6 25.7 TPGS-Free Formulation (DM10017/DCN 930047624) 500 382 1220 103.5 330.6 CByB6F1 Hybrid 50 16.1 29 4.4 7.9 Mice 28-day 150 171 426 46.3 115.4 oral exploratory tox study 500 922 2310 249.9 626.0 (DM09022/DCN 930050534) Rat Juvenile 40 28 21.6 7.6 5.9 Development 125 456 268 124 73 PND 21-90, oral (DN11187) 400 287 196 78 53
Monkey 1 week, oral gavage (DM08018) 30 0.483 0.24 0.1 0.07 150 5.44 6.16 1.5 1.7 300 982 411 266 111 Mouse, Hemizygous (transgenic). 6 (oral gavage), carcinogenicity (DM11012) 25 13.5 13.8 3.7 3.7 100 256 417 69 113 200 983 1,600 266 434 Rat, 2 year (oral gavage), carcinogenicity (DM11023) 50 (M) 20.7 - 5.6 - 75 (M) 58.1 - 16 - 125 (M) 193 - 52 - 40 (F) - 51.5 - 14 60 (F) - 162 - 44 80 (F) - 202 - 55 CByB6F1 Hybrid Mice 2 oral Toxicokinetic, TPGS-Free Formulation (DM10017/DCN 930047624) 50 16.4 18.6 4.4 5.0 150 90.6 94.9 24.6 25.7 500 382 1220 103.5 330.6 CByB6F1 Hybrid Mice 28-day oral exploratory tox study (DM09022/DCN 930050534) 50 16.1 29 4.4 7.9 150 171 426 46.3 115.4 500 922 2310 249.9 626.0 Rat Juvenile Development PND 21-90, oral (DN11187) 40 28 21.6 7.6 5.9 125 456 268 124 73 400 287 196 78 53